News

Registration Now Open for Catalyst Life Sciences Conference

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), announced that registration is open for the Catalyst Life Sciences Conference. The event will be held October 6-7, 2022 at the Omni Hotel in  Richmond, Virginia.

This conference is designed for scientists, engineers, entrepreneurs, incubators and biohubs, life science companies, technology transfer departments and economic development departments. The format consists of expert panels sharing their knowledge and engaging in dialog with the audience.

Joni L. Rutter, Ph.D. will be a keynote speaker. Dr. Rutter is the Acting Director of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). NCATS was established to transform the translational process so that new treatments and cures for disease can be delivered to patients faster.

Expert panel topics include: Best Practices for Building a High-Potential Company, Scientists and Engineers as Entrepreneurs, Raising Capital, Establishing and Building Ecosystems, Growing Pharmaceutical Manufacturing and R-D Cluster, and Partnering with Companies and Healthcare Systems. For the full agenda and speakers, visit: https://www.virginiacatalyst.org/agenda.html.

“The Virginia Catalyst and our major Virginia-based research universities, along with Virginia Bio are excited to host a major life sciences conference to share best practices and encourage collaborations. It is through this collaborative ecosystem that we are improving human health and further developing our life science economy by creating innovative companies, capital formation, and job creation,” said Michael Grisham, President & CEO, Virginia Catalyst.

To register: https://www.virginiacatalyst.org/registration.html

Recent News

11/10/2026

Luminoah Raises $25 Million Series B to Expand Access to Its FDA-Cleared Enteral Feeding System

Luminoah, a medical technology company modernizing enteral nutrition, today announced a $25 million Series B financing led by Sandbox Clinical Ventures, with participation from the Blue Venture Fund, GV (Google Ventures), Sands Capital, Texas Medical Center Venture Fund, the CU Healthcare Innovation Fund, the American Gastroenterological Association GI Opportunity Fund, and existing investors. The Series …

11/04/2026

$6 Million in Philanthropic Gifts Establishes UVA Biotech Innovation Fund

The University of Virginia Paul and Diane Manning Institute of Biotechnology received gifts totaling $6 million from philanthropists to establish the UVA Biotech Innovation Fund. This fund will provide long-term support for the UVA SPARK Innovative Medicines program, helping accelerate promising discoveries toward new treatments and cures. “The mission of the UVA Manning Institute of …

10/29/2026

ReAlta Life Sciences Launches KnowHIE, a New Online Educational Resource for Families of Babies Diagnosed with Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the launch of KnowHIE.com, a new educational website designed to help families and caregivers better understand neonatal hypoxic ischemic encephalopathy (HIE) …